SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

TITAN BIOTECH

BSE: 524717 22 Aug 2025
Commodities
₹ 445.95
Titan Bio-Tech Ltd. specializes in Specialty Chemicals within the Commodities sector.

TITAN BIOTECH - Share Price & Details

Market Cap
₹369.0
High /Low
1,018 / 374.0
Stock P/E
16.8
Book Value
₹186.0
Dividend Yield
0.45
ROCE
16.9
ROE
₹15.0
Face Value
10.0
PEG Ratio
-72.9
EVEBITDA
₹12.2
Debt
2.80
CMP / FCF
34.8
Debt to equity
₹0.02
NP Ann
21.5
High price all time
1,018
Piotroski score
₹5.0
Graham Number
333.0
No. Eq. Shares
0.83
Net CF
₹2.29
Net profit
22.0
Price to book value
2.42
Interest Coverage
₹36.7
Low price all time
8.57
Industry PE
33.2
Reserves
₹145
Free Cash Flow
₹11.6

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
SOUTHERN GAS LTD.92.625.1085.99161.820.060.03
INDO GULF INDUSTRIES LTD.716.01-1.92713.67-0.200
TITAN BIOTECH LTD.365.5037.66351.694.56369.016.8
KANORIA CHEMICALS & INDUSTRIES1942.4-46.71865.4-1.0736779.6
DIAMINES & CHEMICALS LTD.142.77-23.9122.3-2.44354213.0

Peer Comparison Chart


About TITAN BIOTECH

Titan Bio-Tech Ltd., with Security Code 524717, is a leading player in the Specialty Chemicals industry, categorized under the Commodities sector, offering Equity instruments.


Latest News

Dr Boreham's Crucible: In the shadow of giants, but can this biotech become a tumour-tackling titan?

(19 Aug 2025)
Radiopharm Theranostics (ASX:RAD) is lining up multiple shots at oncology goals. Maybe one, maybe more, will hit the back of the net.
Read more →

Titan Biotech Reports Strong Financial Results, Signaling Positive Growth Trends in August 2025

(14 Aug 2025)
Titan Biotech recently reported its financial results for the quarter ending June 2025, showcasing strong performance with the highest net...
Read more →

Titan Biotech consolidated net profit rises 7.19% in the June 2025 quarter

(14 Aug 2025)
Net profit of Titan Biotech rose 7.19% to Rs 6.86 crore in the quarter ended June 2025 as against Rs 6.40 crore during the previous quarter ended June 2024.
Read more →

Novel 'Dropless' Eye Surgery Technology Could Transform Post-Cataract Care for Millions

(13 Aug 2025)
PainReform (Nasdaq: PRFX) has completed a strategic investment in LayerBio, acquiring a majority equity stake to enter the $9 billion global...
Read more →

Titan Biotech Limited (524717) Expands into New Market - Consistently high yield

(04 Aug 2025)
【Stock Highlights】✌️ Receive exclusive access to profitable stock picks and market strategies from seasoned professionals who understand...
Read more →

Titan Biotech Limited (524717) Signs Major Deal - Capitalize on market opportunities with confidence

(04 Aug 2025)
Titan Biotech Limited (524717) Signs Major Deal ✌️【Market Insights】✌️ Our stock selection strategies have helped investors achieve returns...
Read more →

Company Updates